Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emibetuzumab - Eli Lilly and Company

Drug Profile

Emibetuzumab - Eli Lilly and Company

Alternative Names: Anti-c-MET-monoclonal-antibody-Eli-Lilly; c-MET monoclonal antibody - Eli Lilly; c-MET-mAb-Eli-Lilly; cMET antibody - Eli Lilly; LA-480; LY-2875358

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer
  • Phase I/II Cancer

Most Recent Events

  • 08 Sep 2021 Phase II development is ongoing in Non-small cell lung cancer (Combination therapy, Metastatic disease, First-line therapy) in United Kingdom, Denmark, France, Germany, Italy, Netherlands, Spain, South Korea and Taiwan (NCT01897480)
  • 24 Jan 2018 Eli Lilly completes a phase I/II trial in Cancer (Late stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02082210)
  • 06 Jun 2017 Safety and efficacy data from the phase II Balise trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top